Recent Updates
Recently added Catalysts
ADCT Positive Sentiment Score: 85/100

ADC Contract Manufacturing Market, 2035 - Surging Demand for Antibody Drug Conjugates Driving Growth

Key Takeaway: The ADC contract manufacturing market is set for substantial growth, estimated to reach approximately $6.87 billion by 2035. This growth is largely driven by rising demand for antibody drug conjugates (ADCs) as effective cancer therapeutics. The manufacturing process remains complex and requires advanced expertise, prompting developers to outsource their production needs to contract manufacturers. Notably, North America is home to over 50% of these manufacturers, underscoring its central role in this market.

Market Sentiment Analysis

POSITIVE FACTORS

  • The ADC contract manufacturing market is projected to grow significantly, reaching ~$6.87 billion by 2035.
  • There is strong demand for antibody drug conjugates due to their potential in targeting cancers.
  • Over 260 ADC candidates are currently being evaluated in clinical trials, which indicates robust pipeline activity.

Full Press Release Details

Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "ADC Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Antibody Isotype, Type of Payload, Type of Linker, and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering.
The global ADC contract manufacturing market is estimated to be worth $1.79 billion in 2024 and is expected to grow at a CAGR of 13% during the forecast period, reaching ~$6.87 billion by 2035.
The study consists of industry trends, detailed market analysis, service provider landscape, competitiveness landscape, recent expansions, partnerships and collaborations, capacity analysis, clinical trial analysis, likely partner analysis, demand analysis, value chain analysis, market impact analysis, and market forecast and opportunity analysis. The growth in the ADC contract manufacturing market size over the next decade is likely to be the result of anticipated increase in demand for antibody drug conjugates.
In recent years, antibody drug conjugates (ADC) have emerged as a potent class of therapeutics targeting a wide range of cancers including solid tumors and hematological tumors. These complex molecules consist of an antibody, which is attached to biologically active, cytotoxic agents through chemical linkers. ADC therapeutics possess enhanced stability, target specificity, tumor selectivity and pharmacokinetic properties.
These properties have supported extensive research and development initiatives being undertaken for the advancement of ADC therapies to the market. In this context, the current ADC pipeline features the presence of over 260 candidates being evaluated in clinical trials, along with 23 ADC therapeutic programs that have already been approved by various regulatory agencies. The potential of such therapies in selectively targeting tumor cells, while limiting off target toxicities have paved the way for their success and widespread application in the healthcare industry.
However, the ADC manufacturing process is highly complex and is fraught with several challenges, including drug / linker side reactions, exposure to toxicity, contamination and up-scaling. Additionally, the manufacturing process requires significant expertise and use of cutting-edge technologies, which are highly cost intensive. Therefore, the ADC developers prefer outsourcing the manufacturing operations to ADC contract manufacturers. With an intent of cost saving, ADC therapy developers are continually utilizing the experience, capabilities and manufacturing facilities available with the contract manufacturing organizations in order to support their manufacturing operations.
Further, it is worth mentioning that the CMOs engaged in ADC contract manufacturing are actively undertaking initiatives to become one-stop shops and mitigate the challenges associated with technology transfer and scale-up. Considering the increasing demand for ADCs and the increasing preference for outsourcing operations by drug developers, the ADC contract manufacturing market is likely to witness substantial market growth during the forecast period.
Overall Market Landscape of ADC Contract Manufacturers: Majority of the Contract Manufacturers are Based in North America
The ADC contract manufacturing market landscape features the presence of 30 large, mid-sized and small companies. Over 45% of the companies were established before 2000, demonstrating extensive experience and expertise in the contract manufacturing industry. Examples of companies, established before 1980 (in alphabetical order) include Lonza, MilliporeSigma, Sartorius and Sterling Pharma Solutions.
Further, it is worth highlighting that 50% of the ADC contract manufacturers are based in North America. Within Europe, Switzerland emerged as the hub of ADC contract manufacturers. Notably, 43% of the companies offer all types of manufacturing services related to ADCs. Moreover, industry stakeholders are actively undertaking expansion initiatives for their product / service portfolios to become one-stop shops for mitigating the challenges associated with technology transfer and scale-up.
Key Players in ADC Contract Manufacturing Market
Examples of key ADC contract manufacturing organizations (CMOs) (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie Contract Manufacturing, Abzena, CARBOGEN AMCIS, Catalent Pharma Solutions, Cerbios-Pharma, Formosa Laboratories, GBI, Lonza, MabPlex, Millipore Sigma, Piramal Pharma Solutions, Sterling Pharma Solutions and WuXi Biologics. This market report includes an easily searchable excel database of all the ADC contract manufacturing organizations.
Report Attribute Details
No. of Pages 510
Forecast Period 2024 - 2035
Estimated Market Value (USD) in 2024 $1.79 Billion
Forecasted Market Value (USD) by 2035 $6.87 Billion
Compound Annual Growth Rate 13.0%
Regions Covered Global
ADC Contract Manufacturing Market Share Insights
The market research report presents an in-depth analysis of the various companies that are engaged in the global ADC contract manufacturing market, across different segments, as defined below:
Historical Trend: 2019-2021
Base Year: 2022-2023
Forecast Period: 2024-2035
Market Size in 2024: $1.79 Billion
Stage of Development Phase I
Process Component Antibody
HPAPI / Cytotoxic Payload
Conjugation / Linker
Target Indication Solid Tumors
Hematological Tumors
Antibody Generation Second Generation
Antibody Origin Humanized
Antibody Isotype IgG1
Type of Payload Auristatin
DNA Topoisomerase I Inhibitor
Type of Linker Maleimide
Tetrapeptide-based linker
Key Geographical Regions North America
Asia-Pacific and Rest of the World
Key Companies Profiled AbbVie Contract Manufacturing
Catalent Pharma Solutions
Formosa Laboratories
Piramal Pharma Solutions
Sterling Pharma Solutions
(Full list of 30 companies captured is available in the report)
PowerPoint Presentation (Complimentary)
Customization Scope: 15% Free Customization
Excel Data Packs (Complimentary) Market Landscape
Company Competitiveness Analysis
Partnerships and Collaborations
Clinical Trial Analysis
Likely Partner Analysis
Market Forecast and Opportunity Analysis
For more information about this report visit https://www.researchandmarkets.com/r/f1ra9x
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Tags

ADC Contract Manufacturing
Contract Manufacturing
Pharmaceutical Manufacturing

Frequently Asked Questions

What is the estimated value of the ADC contract manufacturing market in 2024?

The ADC contract manufacturing market is estimated to be worth $1.79 billion in 2024.

What is the projected CAGR for the ADC market until 2035?

The ADC contract manufacturing market is expected to grow at a CAGR of 13% until 2035.

How many ADC candidates are currently in clinical trials?

There are over 260 antibody drug conjugate candidates in clinical trials.

Which region has the highest concentration of ADC contract manufacturers?

North America hosts 50% of the ADC contract manufacturers.

What challenges do ADC manufacturers face?

Challenges include drug/linker side reactions, toxicity exposure, and contamination.

Last updated: Jun 20, 2024